Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 11/2014

01-11-2014 | Original Article – Cancer Research

Gastric cancer-derived MSC-secreted PDGF-DD promotes gastric cancer progression

Authors: Feng Huang, Mei Wang, Tingting Yang, Jie Cai, Qiang Zhang, Zixuan Sun, Xiaodan Wu, Xu Zhang, Wei Zhu, Hui Qian, Wenrong Xu

Published in: Journal of Cancer Research and Clinical Oncology | Issue 11/2014

Login to get access

Abstract

Purpose

This study was designed to investigate the role of PDGF-DD secreted by gastric cancer-derived mesenchymal stem cells (GC-MSCs) in human gastric cancer progression.

Methods

Gastric cancer cells were indirectly co-cultured with GC-MSCs in a transwell system. The growth and migration of gastric cancer cells were evaluated by cell colony formation assay and transwell migration assay, respectively. The production of PDGF-DD in GC-MSCs was determined by using Luminex and ELISA. Neutralization of PDGFR-β by su16f and siRNA interference of PDGF-DD in GC-MSCs was used to demonstrate the role of PDGF-DD produced by GC-MSCs in gastric cancer progression.

Results

GC-MSC conditioned medium promoted gastric cancer cell proliferation and migration in vitro and in vivo. Co-culture with GC-MSCs increased the phosphorylation of PDGFR-β in SGC-7901 cells. Neutralization of PDGFR-β by su16f blocked the promoting role of GC-MSC conditioned medium in gastric cancer cell proliferation and migration. Recombinant PDGF-DD duplicated the effects of GC-MSC conditioned medium on gastric cancer cells. Knockdown of PDGF-DD in GC-MSCs abolished its effects on gastric cancer cells in vitro and in vivo.

Conclusions

PDGF-DD secreted by GC-MSCs is capable of promoting gastric cancer cell progression in vitro and in vivo. Targeting the PDGF-DD/PDGFR-β interaction between MSCs and gastric cancer cells may represent a novel strategy for gastric cancer therapy.
Literature
Alberts SR, Cervantes A, van de Velde CJH (2003) Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 14:ii31–ii36PubMed
Ammoun S, Flaiz C, Ristic N et al (2008) Dissecting and targeting the growth factor dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res 68:5236–5245PubMedCrossRef
Beckermann BM, Kallifatidis G, Groth A et al (2008) VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer 99:622–631PubMedCrossRefPubMedCentral
Berardi R, Scartozzi M, Romagnoli E et al (2004) Gastric cancer treatment: a systematic review. Oncol Rep 11:911–916PubMed
Borkham-Kamphorst E, van Roeyen CR, Ostendorf T et al (2007) Profibrogenic potential of PDGF-D in liver fibrosis. J Hepatol 46:1064–1074PubMedCrossRef
Cambien B, Richard-Fiardo P, Karimdjee BF et al (2011) CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRβ in colorectal carcinoma. PLoS ONE 6(12):e28842PubMedCrossRefPubMedCentral
Cao H, Xu W, Qian H et al (2009) Mesenchymal stem cell-like cells derived from human gastric cancer tissues. Cancer Lett 274(1):61–71PubMedCrossRef
Chan JK, Lam PY (2013) Human mesenchymal stem cells and their paracrine factors for the treatment of brain tumors. Cancer Gene Ther 20(10):539–543PubMedCrossRef
Chiba H, Ishii G, Ito TK et al (2008) CD105-positive cells in pulmonary arterial blood of adult human lung cancer patients include mesenchymal progenitors. Stem Cells 26(10):2523–2530PubMedCrossRef
Devarajan E, Song YH, Krishnappa S et al (2012) Epithelial-mesenchymal transition in breast cancer lines is mediated through PDGF-D released by tissue-resident stem cells. Int J Cancer 131(5):1023–1031PubMedCrossRef
Ehnman M, Ostman A (2013) Therapeutic targeting of platelet-derived growth factor receptors in solid tumors. Expert Opin Investig Drugs 23(2):211–226PubMedCrossRef
Guo Y, Yin J, Zha L et al (2013) Clinicopathological significance of platelet-derived growth factor B, platelet-derived growth factor receptor-β, and E-cadherin expression in gastric carcinoma. Contemp Oncol (Pozn) 17(2):150–155
Karnoub AE, Dash AB, Vo AP et al (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449:557–563PubMedCrossRef
Kinnaird T, Stabile E, Burnett MS et al (2004) Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 94:678–685PubMedCrossRef
Lin JT, Wang JY, Chen MK, Chen HC et al (2013) Colon cancer mesenchymal stem cells modulate the tumorigenicity of colon cancer through interleukin 6. Exp Cell Res 319(14):2216–2229PubMedCrossRef
Liu S, Ginestier C, Ou SJ et al (2011) Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 71:614–624PubMedCrossRefPubMedCentral
Lokker NA, Sullivan CM, Hollenbach SJ et al (2002) Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62:3729–3735PubMed
Martin FT, Dwyer RM, Kelly J et al (2010) Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res Treat 124:317–326PubMedCrossRef
McLean K, Gong Y, Choi Y et al (2011) Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest 121(8):3206–3219PubMedCrossRefPubMedCentral
Potapova IA, Gaudette GR, Brink PR et al (2007) Mesenchymal stem cells support migration, extracellular matrix invasion, proliferation, and survival of endothelial cells in vitro. Stem Cells 25:1761–1768PubMedCrossRef
Quante M, Tu SP, Tomita H et al (2011) Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19:257–272PubMedCrossRefPubMedCentral
Salem HK, Thiemermann C (2010) Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 28:585–596PubMedPubMedCentral
Ustach CV, Taube ME, Hurst NJ Jr et al (2004) A potential oncogenic activity of platelet-derived growth factor d in prostate cancer progression. Cancer Res 64:1722–1729PubMedCrossRefPubMedCentral
Wang Z, Kong D, Banerjee S et al (2007) Downregulation of platelet derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and Nuclear Factor- κB Signaling. Cancer Res 67:11377–11385PubMedCrossRef
Wang Z, Kong D, Li Y et al (2009) PDGF-D signaling: a novel target in cancer therapy. Curr Drug Targets 10:38–41PubMedCrossRef
Wang Z, Ahmad A, Li Y et al (2010) Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta 1806(1):122–130PubMedPubMedCentral
Wang M, Zhao C, Shi H et al (2014) Deregulated microRNAs in gastric cancer tissue-derived mesenchymal stem cells: novel biomarkers and a mechanism for gastric cancer. Br J Cancer 110(5):1199–1210PubMedCrossRef
Zhu W, Xu W, Jiang R et al (2006) Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol 80:267–274PubMedCrossRef
Zhu W, Huang L, Li Y et al (2011) Mesenchymal stem cell-secreted soluble signaling molecules potentiate tumor growth. Cell Cycle 10(18):3198–3207PubMedCrossRef
Metadata
Title
Gastric cancer-derived MSC-secreted PDGF-DD promotes gastric cancer progression
Authors
Feng Huang
Mei Wang
Tingting Yang
Jie Cai
Qiang Zhang
Zixuan Sun
Xiaodan Wu
Xu Zhang
Wei Zhu
Hui Qian
Wenrong Xu
Publication date
01-11-2014
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 11/2014
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-014-1723-2

Other articles of this Issue 11/2014

Journal of Cancer Research and Clinical Oncology 11/2014 Go to the issue

Original Article – Clinical Oncology

Filamin A expression correlates with proliferation and invasive properties of human metastatic melanoma tumors: implications for survival in patients

Original Article – Clinical Oncology

Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response—a retrospective study

Original Article – Clinical Oncology

Comparison of different rabbit ATG preparation effects on early lymphocyte subset recovery after allogeneic HSCT and its association with EBV-mediated PTLD

Original Article – Clinical Oncology

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma

Original Article – Clinical Oncology

Allogeneic stem cell transplantation in patients above 55: suggestion for a further stratification of the HCT-CI

Original Article – Cancer Research

The BRAF mutation is associated with the prognosis in colorectal cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits